Direct compression of Guanji Powder Veterinary Grade API is evaluated on a production-scale rotary tablet press fitted with 8 mm round biconcave tooling, a forced feed frame, and an in-die compression force transducer. The API is passed through a 500 µm sieve before charging into a 300 L bin blender together with microcrystalline cellulose USP-NF as diluent, croscarmellose sodium 2–5 wt% as disintegrant, colloidal silicon dioxide 0.2–0.5 wt% as glidant, and magnesium stearate 0.5–1.0 wt% as lubricant. Blending proceeds for 15 min at 12 rpm, with the lubricant added in the final 3 min to limit over-lubrication. The precompression force is set at 4–6 kN and the main compression force at 8–14 kN. Tablet breaking force is maintained at 40–80 N by USP <1217>, friability not more than 1.0% by USP <1216>, and disintegration below 15 min in 0.1 N HCl at 37°C by USP <701>. Dissolution is monitored with USP <711> apparatus 2 at 50 rpm, and blend uniformity must produce an acceptance value ≤15 by USP <905>. If the powder flow function coefficient falls below 4.0 by ASTM D6773, loss-in-weight feeding drift exceeds ±5% and content uniformity risk increases sharply; at that point, direct compression is replaced by a granulation route. Published compaction data for this specific API configuration are limited; a compaction simulator should therefore map Heckel yield pressure, elastic recovery, and ejection shear stress before pilot scale-up. The terminal product is an immediate-release veterinary tablet, released with assay 90.0–110.0% of label by USP <1225>, moisture not more than 3.0% w/w by USP <921>, and in-process tablet weight checked at ±3% of target.

What Happens When Guanji Powder Is Sterile-Filtered into a Multi-Dose Injection?

Injectable solution development starts with equilibrium solubility screening of Guanji Powder Veterinary Grade API in Water for Injection across a pH interval of 3.0–8.5; the selected buffer is constrained by target-species venous tolerance and API degradation kinetics. The bulk solution is compounded in 316L stainless steel jacketed tanks with impeller agitation at 40–60 rpm. After complete dissolution, the pH is adjusted with 0.1 N HCl or 0.1 N NaOH and tonicity is corrected with sodium chloride or dextrose to 280–320 mOsm/kg by freezing-point osmometry per USP <785>. For heat-stable lots, terminal sterilization at 121°C for 15 min per USP <1229.5> is preferred. When thermal exposure is not acceptable, the solution is filtered through a 0.22 µm PVDF membrane with pre-filtration bioburden not exceeding 10 CFU/100 mL per 21 CFR 211.111. Filter integrity testing is performed by bubble point or pressure decay using the membrane manufacturer’s specified pressure; no batch is released without a post-filtration integrity test. If the product is to be a multi-dose vial, benzyl alcohol at 0.9% v/v may be incorporated provided the formulation passes USP <51> category 1 preservative efficacy; single-dose presentations are filled without preservative. For injectable suspensions, particle size reduction through a wet bead mill is performed to a d90 below 20 µm by laser diffraction per USP <429>, and sedimentation ratio is held between 0.90 and 1.00 after 24 h. The terminal product is filled into amber Type I glass vials with butyl rubber closures per USP <381>; fill volume overage of 0.15–0.30 mL is applied to compensate for needle extraction loss.

Capsule Fill Development and Powder Flow Metrics

Capsule filling of Guanji Powder Veterinary Grade API on a dosator-type encapsulator requires target fill weight derived from tapped density per USP <616>, angle of repose, and flow function coefficient measured by ring shear per ASTM D6773. Fill formulations are built with lactose monohydrate or anhydrous dibasic calcium phosphate as filler, croscarmellose sodium 2–4 wt% as disintegrant, and magnesium stearate 0.5 wt% as lubricant. The powder is blended in a 100 L tumble blender for 15 min at 12 rpm. If the flow function coefficient is below 4.0, colloidal silicon dioxide is added at 0.2–0.5 wt% until flow improves. Capsule bodies are filled to a target fill weight with in-line weight control set at ±3%; filled capsules are passed through a metal detector with 0.8 mm ferrous sensitivity and checkweighed at production speed. Content uniformity is tested on 10 capsules at pre-validation by USP <905>; the acceptance value must not exceed 15.0. For moisture-sensitive API, a desiccant canister is inserted in the HDPE bottle and the filled capsule moisture is controlled to not more than 3.0% w/w by USP <921>. The terminal product is a veterinary capsule for oral administration; release assay is 90.0–110.0% label claim by USP <1225>, disintegration below 15 min in 0.1 N HCl at 37°C by USP <701>, and dissolution by USP <711> apparatus 2 at 50 rpm with sinkers for immediate-release capsules.

When Guanji Powder Veterinary Grade API is formulated as an oral dry powder for single-dose sachets or bulk drinking-water packs, the primary processing target is dispersibility and dose uniformity under farm conditions. The API is dry blended with dextrose monohydrate and anhydrous citric acid in a double-cone blender at 20 rpm for 15 min; fumed silica at 0.2 wt% is added as glidant. The blend is packaged into foil-lined laminate sachets on auger fillers with fill weight control at ±5% for 10 g packs or ±1 g for 100 g packs. Sachet seal strength is tested by ASTM F88 with minimum 15 N/15 mm seal peel. Bulk powder for drinking water is packed in 1 kg HDPE jars; moisture content is held at not more than 2.5% w/w by USP <731>. For field use, the powder is added to drinking water at a concentration based on mg per kg body weight; uniform dissolution in cold water at 10–15°C must be verified by a 60-second stir test. If the API has limited cold-water solubility, polysorbate 80 at 0.1–0.5% v/v may be added as wetting agent, but published data for Guanji Powder aqueous solubility in cold water is limited. Pilot field trials must include water hardness up to 300 mg/L as CaCO₃ and residual chlorine up to 2 ppm free chlorine. The terminal product is an oral powder released with identification, assay 90.0–110.0% label by USP <1225>, loss on drying not more than 2.5% w/w, and microbial limits per USP <61> and <62>.

When Wet Granulation Is Introduced to Improve Tablet Compressibility

If direct compression of Guanji Powder Veterinary Grade API fails due to capping or low tensile strength, wet granulation is applied in a top-spray fluid-bed granulator equipped with a 1.0 mm two-fluid nozzle. The dry binder, either polyvinylpyrrolidone K30 at 3–5 wt% or hydroxypropyl cellulose at 2–4 wt%, is dissolved in purified water to form a binder solution of 5–10 wt% solids. The API and diluent are loaded into the fluid-bed bowl and preheated to 30°C ±2°C. Spray rate is set to 20–30 g/min per kg batch at atomizing air pressure 1.5–2.5 bar. Inlet air temperature is maintained at 55–65°C and product temperature at 30–38°C; final granule moisture is dried to 1.5–3.0% w/w using loss on drying per USP <731>. The dried granules are milled through a 0.8 mm conical mill at 1500 rpm and blended with disintegrant and lubricant before tablet compression. Granule flow is measured by bulk/tapped density ratio or ring shear; the granulate must have a compressibility index below 20% per USP <1174>. If the API is moisture-labile, aqueous granulation is contraindicated; dry granulation by roller compaction at roll force 8–15 kN/cm and gap 1.0–1.5 mm is substituted. The terminal product is either a compressible granule intermediate or a final oral granule dosed in sachets; release for granule intermediate includes particle size distribution, loss on drying, and blend uniformity per USP <905> with acceptance value ≤15.

Carryover Control in Medicated Premix Is Governed by Sequential Dilution Geometry

Veterinary premix manufacture from Guanji Powder Veterinary Grade API involves dilution into a feed carrier such as ground corn cob, limestone flour, or rice hulls. A sequenced addition is required: the API is first pre-blended 1:10 with a portion of the carrier in a V-blender for 10 min at 12 rpm. This pre-blend is then transferred to a horizontal ribbon mixer with a working volume of 500 L and mixed for 15 min at 30 rpm. Homogeneity testing is performed by collecting 10 stratified thief samples and analyzing by a validated HPLC method per USP <1225>; the coefficient of variation must be ≤5.0% at the 95% confidence level. Carryover control is governed by 21 CFR Part 225.30; the validated cleaning procedure must demonstrate residue below the carryover limit calculated from the next product’s lowest labelled dose. Dust extraction at transfer points captures airborne dust with a minimum face velocity of 0.5 m/s by ACGIH industrial ventilation guidelines. The terminal product is a medicated premix packaged in 25 kg multiwall paper bags with polyethylene liner; each bag is labelled with active ingredient concentration, mixing instructions, withdrawal period, and applicable medicated feed licence statement.

For oral solution/drench applications, a concentrated stock solution of Guanji Powder Veterinary Grade API is prepared with purified water, a preservative, and a buffering agent; the batch is filtered through a 5 µm clarifying filter before filling into amber PET or HDPE bottles with tamper-evident caps. Target pH is set between 3.5 and 7.0 depending on API stability; citric acid–sodium citrate buffer at 10–50 mM is used to control pH drift. If oxidative degradation is a concern, sodium metabisulfite at 0.1% w/v may be added, but compatibility with the API must be confirmed by forced degradation studies per ICH Q1B. The solution is blended in a 200 L stainless steel tank with bottom-mounted propeller and recirculation loop; dissolution time is monitored by in-line UV absorbance at the API’s wavelength maximum. Final product is tested for appearance, pH per USP <791>, assay 90.0–110.0% label per USP <1225>, preservative content, and microbial enumeration per USP <61> and <62>. Drinking water dosing pumps are calibrated to deliver ±2% of the intended metered volume over 24 h; field mixing accuracy is checked with a conductivity meter if a tracer salt is included at 0.1% w/v. The terminal product is an oral drench or liquid feed additive with a defined withdrawal period; storage stability is assigned based on a bracketed ICH stability protocol at 25°C/60% RH and 40°C/75% RH for 12 months.